Interleukin-12 as an adjuvant for mucosal vaccination against pneumococcal disease.
Phase of Trial: Phase II
Latest Information Update: 23 May 2017
At a glance
- Drugs Interleukin-12 (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- Acronyms Mucosal IL-12 Pneumovac
- 01 Oct 2011 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 07 Apr 2008 New trial record.